# Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer

> **NCT01232829** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 18 (actual)

## Conditions studied

- Adenocarcinoma of the Pancreas
- Recurrent Pancreatic Cancer
- Stage IV Pancreatic Cancer

## Interventions

- **DRUG:** gamma-secretase/Notch signalling pathway inhibitor RO4929097

## Key facts

- **NCT ID:** NCT01232829
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2012-07
- **Final completion:** 2014-05
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2014-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01232829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01232829, "Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01232829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*